# CyGenica Pvt

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cygenica-pvt

- Industry: Biotechnology
- Headquarters: Pune, India
- Website: www.cygenica.com
- Total disclosed funding: $1.4M
- Latest round: Seed (Jun 8, 2021)
- Investors on record: 2

## About

CyGenica Pvt Ltd. is a biotechnology company focused on enhancing therapeutic outcomes for patients through advanced intracellular delivery technology. Their innovative solutions target the treatment of cancer and rare genetic diseases, aiming to improve patient care.CyGenica Pvt Ltd. specializes in the advancement of intracellular therapeutics delivery systems to optimize treatment efficacy. Founded in 2017 in Pune, India, by Nusrat Sanghamitra, who has a background in healthcare innovation, the company has secured USD 1.4 mn in SEED funding led by SOSV, with participation from VOYAGERS Health-Tech Fund. As of June 8, 2021, this funding round marks their total capital raised at USD 1.4 mn, with the focus of their investments directed towards enhancing their drug delivery technology.CyGenica specializes in advanced intracellular therapeutics delivery technology designed to enhance the effectiveness of treatments for patients with cancer and rare genetic diseases. The company’s core offering focuses on the safe and targeted delivery of therapeutics, addressing the critical challenge of ensuring optimal therapeutic outcomes. By improving the patient experience through innovative delivery mechanisms, CyGenica aims to provide solutions that cater to healthcare providers, pharmaceutical companies, and ultimately, the patients who benefit from these therapies. The company serves a diverse client base across various geographical markets, including North America, Europe, and Asia, where it partners with healthcare systems and research institutions to deploy its technologies effectively.In 2023, CyGenica reported a revenue of USD 154,035.30, with an EBITDA of USD 47,023.60. The company generates revenue through strategic partnerships and collaborations with healthcare providers and pharmaceutical firms, focusing on direct-to-consumer and B2B transactions. Their business model leverages these partnerships to facilitate the adoption of its therapeutics delivery systems in clinical settings, deriving revenue streams from licensing agreements, subscription models, and transactional dealings tied to its flagship therapeutic delivery solutions, tailored according to client needs and market conditions.CyGenica plans to utilize the USD 1.4 mn raised in Seed funding to accelerate the development of its drug delivery technology. The company aims to introduce new products designed to enhance therapeutic delivery systems, with specific launch timelines set for the upcoming year. Additionally, CyGenica intends to expand into new markets, particularly targeting regions in Europe and Asia by 2025, to broaden its reach and impact in the healthcare sector.

## Funding rounds

- Seed, Jun 8, 2021, $1.4M — SOSV, VOYAGERS

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- VOYAGERS (https://capitalatlas.ai/funds/voyagers) — Seed